DRP1-mediated mitochondrial shape controls calcium homeostasis and muscle mass

Mitochondrial quality control is essential in highly structured cells such as neurons and muscles. In skeletal muscle the mitochondrial fission proteins are reduced in different physiopathological conditions including ageing sarcopenia, cancer cachexia and chemotherapy-induced muscle wasting. However, whether mitochondrial fission is essential for muscle homeostasis is still unclear. Here we show that muscle-specific loss of the pro-fission dynamin related protein (DRP) 1 induces muscle wasting and weakness. Constitutive Drp1 ablation in muscles reduces growth and causes animal death while inducible deletion results in atrophy and degeneration. Drp1 deficient mitochondria are morphologically bigger and functionally abnormal. The dysfunctional mitochondria signals to the nucleus to induce the ubiquitin-proteasome system and an Unfolded Protein Response while the change of mitochondrial volume results in an increase of mitochondrial Ca2+ uptake and myofiber death. Our findings reveal that morphology of mitochondrial network is critical for several biological processes that control nuclear programs and Ca2+ handling.

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.

For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.

Software and code
Policy information about availability of computer code Data collection Immunofluorescence microscopy images were acquired using Leica TCS SP5 microscope. Where western blot data was acquired digitally, Image LAB (Bio-Rad) software was used. qPCR data was acquired using the Applied Biosystems 7500 Fast Real Time PCR system software (Thermo) Data analysis Data were analyzed using Prism Graphpad version 6 and 7. Microscopy images analysis was performed using ImageJ software. Densitometric analysis of western blots was performed with ImageJ software.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability Provide your data availability statement here.

nature research | reporting summary
October 2018 Field-specific reporting Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design
All studies must disclose on these points even when the disclosure is negative.

Sample size
Sample size was calculated using size power analysis methods for a prior determination, based on the standard deviation and effect size previously obtained using the experimental methods employed in the study.
Data exclusions Exclusion criteria for animals were applied in case of death, cannibalism and the presence of severe clinical alteration of vita physiological functions. Exclusion criteria for samples were applied in case of histological artifacts (freeze-and cut-damaged tissues), RNA and protein degradation.

Replication
In some instances, animal cohorts were repeated to establish confidence in the reproducibility of data presented. Initial optimization of experimental reagents such as dose response experiments were often performed in multiple mouse strains.
Randomization We included mice from different breeding cages by random allocation to the different cages. Animal cages were randomly assigned to treatment groups.

Blinding
Mouse experiments were not performed with blinding; however, when applicable, experimenters were blinded to the nature of the samples by using number codes until final data analysis was performed.

Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Validation
All antibodies used for western blotting were validated in previous publications from our group or by using positive controls. All western blots were performed in mouse tissues only. Antibodies used for immunofluorescent microscopy were validated using positive controls and the inclusion of samples labeled with secondary antibodies only.

nature research | reporting summary
October 2018 Commonly misidentified lines (See ICLAC register) Name any commonly misidentified cell lines used in the study and provide a rationale for their use.

Palaeontology Specimen provenance
Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).

Specimen deposition
Indicate where the specimens have been deposited to permit free access by other researchers.

Dating methods
If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.
Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Wild animals
The study did not involve wild animals Field-collected samples The study did not involve field-collected samples

Ethics oversight
All experimental protocol were approved by the Italian Ministry of Health, Office 5 (authorization number 1060/2015 PR) Note that full information on the approval of the study protocol must also be provided in the manuscript.

Human research participants
Policy information about studies involving human research participants

Ethics oversight
Identify the organization(s) that approved the study protocol.
Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data
Policy information about clinical studies All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration
Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.

Study protocol
Note where the full trial protocol can be accessed OR if not available, explain why.

Data collection
Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.

Outcomes
Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.

ChIP-seq Data deposition
Confirm that both raw and final processed data have been deposited in a public database such as GEO.
Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links
May remain private before publication.
For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.

Files in database submission
Provide a list of all files available in the database submission.